Downregulation of neuronal nitric oxide synthase in the rat remnant kidney.
Chronic renal failure is associated with disturbances in nitric oxide (NO) production. This study was conducted to determine the effect of 5/6 nephrectomy (5/6 Nx) on expression of intrarenal neuronal nitric oxide synthase (nNOS) in the rat. In normal rat kidney, nNOS protein was detected in the macula densa and in the cytoplasm and nuclei of cells of the inner medullary collecting duct by both immunofluorescence and electron microscopy. Western blot analysis revealed that 2 wk after 5/6 Nx, there were significant decreases in nNOS protein expression in renal cortex (sham: 95.42+/-15.60 versus 5/6 Nx: 47.55+/-12.78 arbitrary units, P<0.05, n = 4) and inner medulla (sham: 147.70+/-26.96 versus 5/6 Nx: 36.95+/-17.24 arbitrary units, P<0.005, n = 8). Losartan treatment was used to determine the role of angiotensin II (AngII) AT1 receptors in the inhibition of nNOS expression in 5/6 Nx. Losartan had no effect on the decreased expression of nNOS in the inner medulla, but partially increased nNOS protein expression in the cortex of 5/6 Nx rats. In contrast, in sham rats losartan significantly inhibited nNOS protein expression in the cortex (0.66+/-0.04-fold of sham values, P<0.05, n = 6) and inner medulla (0.74+/-0.12-fold of sham values, P<0.05, n = 6). nNOS mRNA was significantly decreased in cortex and inner medulla from 5/6 Nx rats, and the effects of losartan on nNOS mRNA paralleled those observed on nNOS protein expression. These data indicate that 5/6 Nx downregulates intrarenal nNOS mRNA and protein expression. In normal rats, AngII AT1 receptors exert a tonic stimulatory effect on expression of intrarenal nNOS. These findings suggest that the reduction in intrarenal nNOS expression in 5/6 Nx may play a role in contributing to hypertension and altered tubular transport responses in chronic renal failure.
Roczniak
A
A
Department of Medicine, University of Ottawa and Ottawa General Hospital, Ontario, Canada.
Fryer
J N
JN
Levine
D Z
DZ
Burns
K D
KD
D000704:Analysis of Variance; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D015153:Blotting, Western; D002467:Cell Nucleus / Q000648:ultrastructure; D046508:Culture Techniques; D003593:Cytoplasm / Q000648:ultrastructure; D004195:Disease Models, Animal; D015536:Down-Regulation / Q000502:physiology; D005455:Fluorescent Antibody Technique; D007672:Kidney Cortex / Q000294:innervation* / Q000473:pathology; D007679:Kidney Medulla / Q000294:innervation* / Q000473:pathology; D019808:Losartan / Q000494:pharmacology; D008297:Male; D009392:Nephrectomy; D009474:Neurons / Q000201:enzymology*; D019001:Nitric Oxide Synthase / Q000032:analysis / Q000235:genetics / Q000378:metabolism*; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000032:analysis* / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D012680:Sensitivity and Specificity
D057911:Angiotensin Receptor Antagonists; D012333:RNA, Messenger; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D019001:Nitric Oxide Synthase; D019808:Losartan